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ABSTRACT 
Background 
Tinea capitis is the most common cutaneous fungal infection in children. 
Objectives 
This review aims to evaluate the differences that exist between medications for the treatment of tinea 
capitis, to determine whether there are any significant adverse effects associated and to define the 
usefulness of sample collection methods. 
Methods 
We conducted a systematic literature search of available papers using the databases PubMed, OVID, 
Cochrane Libraries and ClinicalTrials.gov. 21 RCTs and 17 CTs were found. 
Results 
Among the different antifungal therapies (oral and combination thereof), continuous itraconazole and 
terbinafine had the highest mycological cure rates (79% and 81%, respectively), griseofulvin and 
terbinafine had the highest clinical cure rates (46% and 58%, respectively) and griseofulvin and 
terbinafine had the highest complete cure rate (72% and 92%, respectively). Griseofulvin more 
effectively treated Microsporum infections; terbinafine and itraconazole more effectively cured 
Trichophyton infections. Only 1.0% of children had to discontinue medication based on adverse 
events. T. tonsurans was the most common organism found in North America, and hairbrush collection 
method is the most efficient method of sample collection. Additionally, using a hairbrush, toothbrush or 
cotton swab to identify the infecting organism(s) is the least invasive and most efficient method of tinea 
capitis sample collection in children. 
Conclusions 
Current dosing regimens of reported drugs are effective and safe for use in tinea capitis in children. 
INTRODUCTION 
Tinea capitis is a superficial cutaneous fungal infection or dermatophytosis of the scalp also referred to 
as ringworm. The infection originates from a variety of sources including humans, animals and soil. It 
remains the most common cutaneous fungal infection in children, most prevalent between 3 and 
7 years of age.1   The diagnosis of tinea capitis is made by a focused history, physical examination, 
trichoscopy and microscopy test. Methods of sample collection for microscopy diagnosis vary among 
location and investigator. The epidemiological distribution of tinea capitis has diverse geographical and 
seasonal variations depending on several factors, including lifestyle, population, migration of people and 
climatic conditions. This review aims to evaluate the differences between medications for the treatment 
of tinea capitis, to determine whether there are any significant adverse effects associated with this 
treatment and to determine the usefulness of the different diagnosing methods. 
METHODS 
Search strategy and selection criteria 
A systematic review examined randomized controlled trials (RCTs) and clinical trials of tinea capitis in 
children. No date ranges were set. Potentially relevant studies were identified through a literature 
search for articles published as of 1 June 2017, using multiple research databases (PubMed, Ovid, 
Scopus, Cochrane libraries and ClinicalTrials.goǀ). The searĐh ideŶtified aŶy ĐitatioŶs ĐoŶtaiŶiŶg ͚tiŶea 
Đapitis͛ or ͚riŶgǁorŵ of the sĐalp͛ aŶd ͚ĐhildreŶ, Đhild or ĐhildreŶ, Đhildhood or paediatriĐ or youŶg͛. 
Additional limits included removing duplicates, and searches were limited to English only articles, 
humans and children aged 18 years or younger. References within retrieved articles were also searched 
to identify additional articles that may have been missed in the primary database search. 
Study eligibility 
Studies were selected for analysis if the following criteria were met: (a) clinical trial (CT) or RCT (b) 
participants were 18 years of age or younger; (c) tinea capitis was clinically (as defined by investigators) 
and mycologically (as defined by mycological testing) diagnosed and (d) reported efficacy rates (e.g. 
mycological cure, clinical cure, complete cure) and/or safety measures. Papers which met explicit 
inclusion criteria were included for full‐text review. 
Evaluation of efficacy 
Primary measures were efficacy rates examined across eligible studies and included mycological cure, 
clinical cure and complete cure. Mycological cure was defined as negative mycological testing (e.g. 
negative culture, negative potassium hydroxide (KOH), periodic acid–Schiff stain (PAS)). Clinical cure was 
defined as the absence of signs and symptoms of tinea capitis (could be Total Signs and Symptoms 
(TSSS) score of 0 or a clinical parameter score of 0). Complete cure was defined as both mycological and 
clinical cure. The TSSS is a scale that rates the severity of 5 different signs and symptoms (erythema, 
desquamation/scaling, papules, pustules and pruritus) on a 4‐point scale (0, absent; 1, mild; 2, 
moderate; 3, severe). These were summed to obtain a TSSS, with a maximum value of 15 points.2  
Secondary measures were qualitative evaluation of frequency and severity of reported adverse events 
and were obtained for each antifungal drug across all included studies. Study characteristics such as the 
year, location, method of collecting samples for investigation and infecting organisms were also 
reported and analysed. 
RESULTS 
Study characteristics 
Our search yielded 4190 studies (Figure 1). The most common organisms found in each continent 
were T. violaceum in Africa,3-5 M. canis in Asia,6-10   M. canis in Europe,11-22  T. tonsurans in North 
America5, 23-37 and M. canis in South America5, 38, 39 (Fig. 2). The most common hair sample collection 
method was the Wood's light examination/light microscopic examination 
(9/18)3, 4, 10, 15, 17, 18, 22, 33, 36 (Table 1). Across all studies, five oral antifungals (terbinafine, griseofulvin, 
itraconazole, ketoconazole and fluconazole) were examined in 3998 children.4-10, 13-18, 20, 21, 24, 25, 27-29, 32-
40   A few included studies also evaluated the efficacy and safety of combinations of oral and topical 
therapies across a total of 833 treated children11, 12, 18, 19, 22, 23, 26, 30, 31 and 25 children used only topical 
therapies.3 
Efficacy rates 
Terbinafine was evaluated in twelve included studies using weighted averages4, 7-10, 15, 16, 20, 24, 37-39 with a 
pooled total of 1592 children (Table 2). Using the predefined definition of mycological cure (negative 
mycological testing) and after one or 2 weeks of treatment, terbinafine had a weighted average of 
53.8% (57/106) children mycologically cured. Mycological cure after 4 weeks of treatment was 81.4% 
(48/59) and after six to 8 weeks of treatment 50.9% (535/1052). Clinical cure was 58.1% (50/86) and 
was evaluated in one study after one to 2 weeks of treatment. After one or 2 weeks of treatment, the 
average was 54.8% (57/104), and after 4 weeks of treatment, the average measured at week 6 was 
91.7% (22/24), at week 8 was 69.4% (25/36) and then week 12 post‐treatment was 60.9% (42/69). 
Twelve studies examined the effects of griseofulvin.6, 7, 9, 13-15, 24, 25, 28, 29, 38, 40  The mycological cure after 
6 weeks of treatment was a weighted average of 51.5% (421/818) and after 8 weeks of treatment was 
67.2% (43/64). The clinical cure after 6 weeks of treatment was a weighted average of 46.6% (373/801). 
Complete cure had a weighted average after 6 weeks of treatment of 32.8% (263/801) and after 
8 weeks the average increased to 71.8% (46/64). 
Itraconazole continuous therapy was found in two studies,17, 35 and the weighted average of the 
mycological cure at 12 weeks of the capsules is 79.0% (83/105). Ketoconazole was found in four 
studies,14, 25, 28, 29 and the weighted average of the mycological cure measured at 12 weeks was 15.1% 
(11/73). 
Terbinafine for 4 weeks was combined with either selenium sulphide shampoo11 or 1% terbinafine 
cream22 for a mycological cure weighted average of 46.8% (61/126). Griseofulvin plus ciclopirox or 
selenium sulphide shampoo had a mycological cure weighted average of 32.7% (32/98). Itraconazole 
capsules plus selenium sulphide shampoo had a mycological cure weighted average of 79.1% (53/67). 
Efficacy rates per species 
Nine RCTs (9/21)3, 4, 7, 11, 15, 24, 26, 28, 39 and nine CTs (9/17)5, 16, 18-22, 30, 35 reported cure rates that met our 
inclusion criteria. The fungi genus Microsporum (canis and audouinii),an exophytic invasion, was 
identified in combination therapy,11, 18, 19, 22 griseofulvin,15, 24, 38 fluconazole,5 itraconazole,35 terbinafine,8, 
15, 20, 24, 38, 39 squalamine3  and ketoconazole.28  The fungi genus Trichophyton (tonsurans, violaceum, 
mentagrophytes, rubrum, schoelini and verrucosum), an endophytic invasion, was identified in 
combination therapy,11, 18, 26, 30 griseofulvin,15, 24, 28, 38 fluconazole,5 itraconazole,33 terbinafine8, 15, 16, 24, 38, 
39 and ketoconazole.28  One RCT reported the species Penicillium and Scopulariopsis for the treatment 
with ketoconazole with only two participants and 100% mycological cure rate.28  One topical treatment 
squalamine was tested in the Microsporum species with none of the five participants cured.3 
Griseofulvin more effectively treated Microsporum than Trichophyton infections (mycological cure rate 
60% and 54%, complete cure rate 49% and 40%, respectively) (Table 3). This is further improved with 
the combination of selenium shampoo to oral griseofulvin (mycological cure 61% and 31%, 
respectively). Fluconazole was equally effective in treating both Microsporum and Trichophyton 
infections (mycological cure 94% and 100%, respectively). Lastly, Trichophyton infections were more 
effectively cured than Microsporumwith continuous itraconazole (mycological cure 91% and 74%, 
respectively) and terbinafine (mycological cure 66% and 46%, complete cure 50% and 27%, clinical cure 
69% and 40%, respectively). 
Adverse events reported 
A total of 295 adverse effects (AEs) from terbinafine 51.2% (151/295), griseofulvin 26.8% (79/295), 
fluconazole 12.2% (36/295), itraconazole 8.5% (25/295) and ketoconazole 1.4% (4/295) related to drug 
use were reported (Table 3). No adverse events were considered life‐threatening, and all were mild to 
moderate in severity and transient. Therefore, a total 318 children experienced some level of AEs 
related to drug use, at a frequency of 6.5% (318/4856). A total of 50 children ceased treatment 1.0% 
(50/4856) due to drug effects (Tables 4 and 5). 
DISCUSSION 
Among the 75 different combinations of antifungal therapies identified in our literature search, 
continuous itraconazole and terbinafine had the highest mycological cure rates; griseofulvin and 
terbinafine had the highest clinical cure rates; and griseofulvin and terbinafine had the highest complete 
cure rate. Adverse events were transient and limited to mild to moderate in severity. Griseofulvin more 
effectively treated Microsporum than Trichophyton infections. Fluconazole was reasonably equally 
effective in treating both Microsporum and Trichophyton infections. Finally, Trichophyton infections 
were more effectively cured than Microsporum with continuous itraconazole and terbinafine. 
Traditionally, griseofulvin is the most widely prescribed medication for tinea capitis treatment in 
children, as it is one of the more cost‐effective and accessible approaches. It is most effective for the 
treatment of Microsporum infections, but it is not available in paediatrics form in many countries. 
Table 6 outlines the paediatric drug availability per country. Microsized and ultramicrosized tablet 
versions of the drug show that co‐administration of griseofulvin with fatty food will tend to reduce the 
difference between the bioavailability of the two types of preparations and microsized will be absorbed 
more easily.41  Griseofulvin is fungistatic and is quickly eliminated from the body so it must be 
continuously given for a long period of time to be effective. This longer duration of treatment may also 
contribute to a higher level of adverse events experienced compared to agents such as itraconazole, 
ketoconazole and fluconazole. A higher dose of griseofulvin is also needed for endothrix infections than 
ectothrix. This may contribute to the reduction in patient compliance and decreased efficacy, 
specifically in children. Griseofulvin, itraconazole and fluconazole are available as liquid suspensions, 
and fluconazole is also available as suppositories which are preferable methods of treatment for young 
children who are unable to swallow capsules and tablets. After puberty, the incidence of tinea capitis 
becomes more infrequent as an increase in fungistatic and fungicidal saturated lipid acids is associated 
with puberty.42 
 
Azole antifungal agents itraconazole and fluconazole, as well as the allylamine agent terbinafine, have 
high affinity for keratinizing tissues, so these agents remain in keratin and hair for a period beyond the 
end of active dosing meaning dosage periods can be shorter than that of griseofulvin. Terbinafine 
for Microsporum infections needs to be given for a longer period of time, 6 to 8 weeks, compared to 
4 weeks for Trichophyton infections. Oral terbinafine accounted for over half of the reported adverse 
events, possibly due to its extensive biodistribution. It is recommended that baseline transaminase is 
monitored in children taking terbinafine.43  A 2016 Cochrane review concluded that the best evidence 
suggests that these newer treatments (terbinafine, itraconazole and fluconazole) have comparable 
results to griseofulvin in children with tinea capitis caused by Trichophytonspecies.44  However, newer 
treatments are more expensive and as this is a fungal infection that generally infects the lower socio‐
economical communities of the world. 
Topical treatment may be useful as an adjunct to systemic therapy to decrease the carriage rate of 
infected species; however, oral treatment is necessary to effectively eradicate tinea capitis.45  
Treatments such as selenium sulphide, ketoconazole or ciclopirox shampoo are not FDA‐approved for 
tinea capitis specifically; however, (likely as they are ineffective on their own) it can be applied 2 to 3 
times per week and left in place for 5 to 10 min for the duration of therapy or at least 2 weeks.45  Some 
experts recommend topical treatment is continued until clinical and mycological cure occurs.45 
Mycological cure should be interpreted with caution, as the presence of a topical antifungal in a culture 
media would likely lead to a false negative result, so a clinical confirmation is necessary. 
Bodyweight is used to determine drug dosing in most paediatric medicine to ensure a safe dose. 
Paediatric weight estimation methods have been varied due to problems with bias, precision and 
restrictions in the population to whom they can be applied. Physicians must rely on parental recall or 
provider estimation as strategies for estimating bodyweight or refer to the child's age or length.46  The 
effectiveness of these methods may be insufficient as most methods overestimate weight in children 
who are underweight and underestimate weight in children who are overweight or obese.46  
Additionally, these methods may not take into account the race and ethnicity of children.46  More recent 
clinical trials have suggested that children require significantly larger weight‐normalized doses to 
approximate the exposure estimates detected in adults.47 
Trichophyton tonsurans is the most common aetiology in North America, and recent data show that it 
accounts for the rise in the prevalence of tinea capitis. T. tonsurans is an anthropophilic dermatophyte 
more likely to infect human skin and hair and can maintain viability for extended periods on inanimate 
objects such as combs, brushes, sheets and blankets. The highest incidence of infection occurs between 
the ages 3 and 7 years old, and boys and girls are equally affected.1  The continued rise 
of T. tonsurans as the primary cause of tinea capitis in North America can be attributed to a few factors. 
For one, the immigrant workers who have found their way into the USA, mostly from countries such as 
Mexico and Puerto Rico since the late 1890s, have been suspected to have carried the organism over 
the border.48  Additionally, many physicians still consider fluorescence (Wood's light examination) to be 
synonymous with tinea capitis, and T. tonsurans does not show up with fluorescence and may not 
contain the classic appearance of black dots. This means many cases of tinea capitis are misdiagnosed as 
other scalp conditions (seborrhoea, dandruff and impetigo) and often inadequately treated, leading to 
spread of the infection. 
Microsporum canis is a zoophillic dermatophyte that causes infection carried by infected animals. It is 
the most common cause of tinea capitis in children in Europe, although cases due to anthropophilic 
dermatophytes such as M. audouinii, Trichophyton soudanense, Trichophyton violaceum are reported 
with increasing incidence since the 1990s. 
Anthropophilic and zoophilic tinea capitis differ clinically, as the latter is characterized by more evident 
inflammatory changes. M. canis tinea capitis develops rapidly as a single round area of alopecia, with 
hair irregularly broken a few mm from the scalp, scales and erythema, associated with itching (Figure 3). 
The incidence is highest in hot months and history frequently reveals contact of the child with a wildcat. 
Tinea capitis due to anthropophilic dermatophytes, on the other hand, is often a chronic condition. 
Several small areas of alopecia due to hair broken at the scalp emergence (black dot tinea capitis) 
associated with mild scalp scaling are a typical feature (Figure 4). Scalp scaling associated or not with 
alopecia is found in family members, which should be checked and treated as they are asymptomatic 
carries. Trichoscopy confirms the diagnosis showing the typical features of tinea capitis, which vary 
depending on the hair type and not on the causative agent.49  Comma hairs, corkscrew hairs and morse‐
code hairs are exclusive typical findings (Figures 3, 4). 
Of the techniques included in our review, the fastest way to diagnose tinea capitis is microscopy which 
provides confirmation of the diagnosis and establishes whether the fungus is small‐spore or large‐spore 
ectothrix or endothrix; however, it is not always the most accurate. Direct microscopy will not yield 
species identification, whereas culturing the scrapings will express the species in the sample, but it will 
not distinguish causative agents from contaminants. Culturing the scrapings should be done to confirm 
diagnosis and provide precise identification of the species for epidemiologic purposes, even though this 
takes extended time (approximately 3 weeks, or longer).50  In the future, PCR‐based techniques and DNA 
sequencings will be used more often as they are even faster than microscopy; they were not used in any 
of our included papers most likely due to the lack of availability of the necessary specialized equipment. 
Over half of the studies in this review used some form of the Wood's light examination as a way to 
initially diagnose the infecting organism; this method is of little significance in western countries as the 
majority of infections are due to T. tonsurans, which does not fluoresce. In North Africa and Europe, 
Microsporum infections still dominate and Wood's light may still be useful as it is the least invasive 
method of organism identification (Figure 2). Hair clippings are not mentioned as a form of collecting 
the sample in our literature search, this is probably due to the fact that not all hair is long enough or not 
all children want a section of their hair to be clipped. The hairbrush method has the least invasive and 
most accurate sample collection process. The cotton swab method was mentioned by one paper38 and 
is similarly a good option as it is simple, inexpensive and useful for areas hard to scrape (eyelids, 
eyebrows) or areas that have lesions. The scalpel and hair plucking methods have better rates of 
identification; however, they are invasive specifically in children and particularly with active infected 
lesions. Diagnosis of inflammatory tinea capitis can sometimes be difficult as microscopy and even 
pathology might give negative results (Figures 5a,b).51 
Infection from fomites and hair care practices all play a role in the acquisition of tinea capitis due to 
anthropophilic dermatophytes.1  Predisposing factors of this type of tinea capitis include large family 
size, crowded living conditions and low socio‐economic status.48, 50, 52  Individuals in contact with an 
infected person should be assessed for asymptomatic carriers of infection and may need to be treated 
to prevent spread of the infection. In case of tinea capitis by zoophilic dermatophytes, pets that may 
have carried the infection should be checked by a veterinarian, sampled by the toothbrush technique 
and treated accordingly, keeping in mind that cat can be asymptomatic carries of Microsporum canis.53  
Fomites that may be infected should be discarded or disinfected with bleach or hot soapy water to 
prevent infection. Recent studies have indicated that it is impractical to keep children recently treated 
with oral therapy out of the classroom, particularly those in higher grade levels, because shedding of 
spores can occur for months, despite therapy.52  Tinea capitis, however, still remains a relatively rare 
entity among infants. One reference cites only 50 known reported cases of tinea capitis in infants less 
than 1 year of age at the time of their evaluation.54  Guidelines for infant care are not established. 
In conclusion, the importance of early diagnosis and proper treatment for children with tinea capitis 
cannot be overstated as the psychosocial impact of permanent baldness in a child's life, and the overall 
lower quality of health is substantial. Current dosing regimens of reported drugs are effective and safe 
for use in tinea capitis in children. Wood's light should not be used as the only method of organism 
identification; this study recommends the use of hairbrushes, toothbrushes or cotton swabs as viable 
alternatives. 
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Figure 1 
Summary of literature search for RCTs and CTs on the treatment of tinea capitis in children 
  
Figure 2 
Map of most common organisms in each country. Countries in grey do not have sufficient information 
to include. 
  
 Figure 3 
Tinea capitis due to Microsporum canis: scaly red patch of alopecia with broken hair shafts; 
trichoscopy shows coma hairs, morse‐code hairs and hair casts. 
 
  
Figure 4 
Tinea capitis due to Tricophyton tonsurans: scaly patches of alopecia; trichoscopy shows corkscrew 
hairs. 
 
  
Figure 5  
Kerion negative pathology and fungal staining. 
 
 
 
 
 
Table 1 
Positives and negatives list of the methods of collection samples for the diagnosis tinea capitis in children 
Collection method Technique Positives Negatives 
Cotton swabbing method 14 A tap water, moistened sterile cotton tip 
applicator is vigorously rubbed and 
rotated over an affected area of scalp for 
maximum 15 s 
 Cotton swabs are readily 
aǀailaďle iŶ ŵost physiĐiaŶs͛ 
offices  Inexpensive  Easy to use  Useful for areas hard to 
scrape (eyelids, eyebrows) or that 
have lesions  Low pain 
 Low efficacy in isolating the 
dermatophytes from scalp  Lack of ability to predict the spore 
load  Must scrub vigorously 
Hair clipping method A few hairs from involved areas of the 
scalp are clipped from scalp 
 Hair clippers are readily 
aǀailaďle iŶ ŵost physiĐiaŶs͛ 
offices  Easy to use  No pain  Inexpensive 
 Risking pain or trauma to the patient  Not all hair can be clipped 
Hair plucking method 19, 26 A few hairs from involved areas of the 
scalp are plucked from scalp 
 Tweezers are readily available 
iŶ ŵost physiĐiaŶs͛ offiĐes  Easy to use  Inexpensive 
 Risking pain or trauma to the patient  Not all hair can be plucked  May remove uninvolved hairs 
Hairbrush culture technique 3, 56 Brush is rubbed on scalp. The friction 
from massaging the bristles around the 
affected areas makes the bristles 
negatively charged so that they pick up 
hairs and scalp scales. The brush is then 
sent to the laboratory 
 Easy to use  Brush covers a greater surface 
area to collect samples  Low pain 
 Hairbrushes are not readily available 
iŶ ŵost physiĐiaŶs͛ offiĐes  Must scrub vigorously  Isolation power at 64%  Incubation period required for the 
hairbrush culture is at least 2 week 
Collection method Technique Positives Negatives 
 Poor results children with closely 
cropped or shaved scalps, or tightly 
braided hair 
Scalpel blade method Obtained by scraping the affected area 
with the blunt side of a scalpel (to avoid 
slicing through the infected hairs) onto a 
piece of folded paper 
 Can tests for KOH easily  Scalpels are readily available 
iŶ ŵost physiĐiaŶs͛ offiĐes 
 Expensive  Risking pain or trauma to the patient  This technique requires some practice 
Toothbrush culture 
technique11, 15, 37 
The friction from massaging the bristles 
around the affected areas makes the 
bristles negatively charged so that they 
pick up hairs and scalp scales 
 Inexpensive  Low pain  Low efficacy in isolating the dermatophytes from scalp and their lack 
of ability to predict the spore load  Toothbrushes are not readily 
aǀailaďle iŶ ŵost physiĐiaŶs͛ offiĐes  Provides greater inoculum for culture 
Wood's light/lamp 
examination4, 10, 16, 20, 38  or light 
microscopy examination6, 13, 24, 31 
Hair is examined and exposed to the 
black light 
 No pain  Easy to use  Expensive  Not readily available in most 
physiĐiaŶs͛ offices  Can only detect Microsporum spp. 
species with a blue‐green fluoresce and 
T. schoenleinii has a dull blue fluoresce 
     
Table 2 
Efficacy rates 
Dose Mycological cure Complete cure Clinical cure 
Griseofulvin 
 Based on weight for 8 weeks Wk 12: 67.2% (n = 64) 
Wk 8: 40.6% (n = 64) 
Wk 12: 71.8% (n = 64) 
 
 Based on weight for 6 weeks Wk 6: 52.3% (n = 321) 
Wk 10: 51.5% (n = 818) 
Wk 10: 32.8% (n = 801) Wk 10: 46.4% (n = 801) 
 10–15 mg/kg/day for 8 weeks 
(plus ciclopirox or selenium 
sulphide shampoo) 
Wk 2: 16.7% (n = 78) 
Wk 4: 37.4% (n = 155) 
Wk 6: 44.4% (n = 45) 
Wk 8: 41.3% (n = 155) 
Wk 12: 32.7%(n = 98) 
  
Itraconazole 
 100 mg/day for 4 weeks (plus 
selenium sulphide shampoo) 
Wk 4: 55.2% (n = 67) 
Wk 6: 68.7% (n = 67) 
Wk 8: 79.1% (n = 67) 
  
 3–5 mg/kg/day for 4 to 
8 weeks 
Wk 12: 79.0% (n = 105) 
  
Ketoconazole 
 3.3–6.6 mg/kg/day for 
2 weeks 
Wk 4: 24.7% (n = 73) 
Wk 12: 15.1% (n = 73) 
  
Terbinafine 
 Based on weight for 1 to 
2 weeks 
Wk 4: 53.8% (n = 106) Wk 12: 54.8% (n = 104) Wk 12: 58.1% (n = 86) 
 Based on weight for 4 weeks Wk 4: 66.3% (n = 83) 
Wk 8: 69.6% (n = 56) 
Wk 12: 81.4% (n = 59) 
Wk 3: 8.3%(n = 24) 
Wk 6: 91.7% (n = 24) 
Wk 8: 69.4% (n = 36) 
Wk 12: 60.9% (n = 69) 
 
 Based on weight for 6 to 
8 weeks 
Wk 6: 50.9% (n = 1052) 
  
 Based on weight for 4 weeks 
plus selenium sulphide 
shampoo or 1% terbinafine 
cream 
Wk 4: 46.8% (n = 126) Wk 4: 32.9% (n = 158) 
 
 
 
Table 3 
Treatment (dosage) Mycological cure Complete cure Clinical cure 
Microsporumspp. Trichophytonspp. Microsporumspp. Trichophytonspp. Microsporumspp. Trichophytonspp. 
Griseofulvin Dose based on 
wgt for 6 to 
8 wks 
Wks 8 to 12:  
60.0% (n = 86) 
Wks 6 to 12:  
54.4% (n = 388) 
Wks 8 to 12:  
48.5% (n = 99) 
Wks 6 to 12:  
39.8% (n = 357) 
Wks 8 to 12:  
57.3% (n = 82) 
Wks 6 to 12: 
 59.0% (n = 339) 
Griseofulvin 
plus selenium 
sulphide 
shampoo 
10 to 15 mg/ 
kg/dy plus 1 to 
2.5% for 8 wks 
Wks 4 to 24: 60.6% 
(n = 33) 
Wks 2 to 8:  
30.7% (n = 238) 
– – – – 
Fluconazole 8 mg/kg/dy for 
8 wks 
Wks 8:  
94.1% (n = 17) 
Wks 8:  
100.0% (n = 44) 
– – – – 
Itraconazolea 3 to 5 mg/ 
kg/dy for 4 to 
8 wks 
Wks 4 to 6: 73.5% 
(n = 34) 
Wks 4 to 8:  
90.9% (n = 22) 
– – – – 
Itraconazolea
plus selenium 
sulphide 
shampoo 
Dose based on 
wgt plus 1 to 
2.5% for 4 wks 
Wks 4 to 8: 93.6% 
(n = 78) 
Wks 2 to 8: 52.7% 
(n = 148) 
– – – – 
Terbinafine Dose based on 
wgt 6 to 8 wks 
Wks 8 to 12: 45.9% 
(n = 170) 
Wks 8 to 12: 
 66.4% (n = 699) 
Wks 10:  
27.0% (n = 152) 
Wks 10: 
 49.5% (n = 667) 
Wks 10:  
39.5% (n = 152) 
Wks 10:  
68.8% (n = 667) 
Terbinafine 
plus selenium 
sulphide 
shampoo or 
terbinafine 
cream 
Dose based on 
wgt plus 1 or 
2.5% or 1% for 
4 wks 
Wks 4 to 24: 26.1% 
(n = 115) 
Wks 4 to 8:  
47.8% (n = 67) 
– – – – 
 
a continuous itraconazole treatment. 
 
Wk, week; Wgt, weight  
Table 4 
Drug Reported 
circulatory 
events 
Reported 
dermatological 
events 
Reported 
gastrointestinal 
events 
Reported 
respiratory 
events 
Reported 
miscellaneous 
events 
Total reported 
drug related 
events 
Number of 
children 
experiencing 
AEs 
Number of 
children disc. 
drug due to 
AE (n=) 
Fluconazole 
(n = 758) LFTa 
– Rash (3/36) AP (6/36) 
Diarrhea (4/36) 
Dyspepsia (1/36) 
Gastritis (4/36) 
Fever (3/36) 
Rhinitis (1/36) 
URTI (1/36) 
Otitis media 
(1/36) 
Headache (5/36) 
Nausea (3/36) 
Vomiting (2/36) 
Unspecified (2/36) 
36 36/758 10/758 
Griseofulvin 
(n = 1665) Nonea 
↑triglyĐerides 
(1/79)b 
Anemia (2/79) 
SGOT (1/79) 
Rash (1/79) AP (10/79) 
Diarrhea (7/79) 
Dyspepsia (3/79) 
Fever (1/79) Headache (12/79) 
Nausea (9/79) 
Weight gain (3/79) 
Vomiting (12/79) 
Unspecified (17/79) 
79 83/1665 15/1665 
Itraconazole 
(n = 521) LFT initially and 
after 4 wks of usea 
– Atopic 
dermatitis (2/25) 
Skin lesions 
(4/25) 
AP (2/25) 
Diarrhea (4/25) 
General events 
(3/25) 
Indigestion 
(2/25) 
Viral infection 
(3/25) 
Epistaxis (1/25) 
Headache (1/25) 
Vomiting (3/25) 
25 23/521 4/521 
Ketoconazole 
(n = 169) LFT initially and 
after 4 wks of usea 
– Urticaria (1/4) AP (2/4) – Nausea (1/4) 4 4/169 0/169 
Terbinafine 
(n = 1718) LFT initially 
and after 6 wks of usea 
Eosinophilia 
(5/151) 
PVE (1/151) 
↑ 
triglycerides(5
/151) b 
↑hepatic 
enzymes(8/15
1) b 
Leucytosis 
(4/151) 
Erythema 
(1/151) 
Itch (2/151) 
ID reaction 
(7/151) 
Pruritus (1/151) 
Urticaria (1/151) 
AP (24/151) 
Diarrhea 
(12/151) 
Obstipation 
(2/151) 
– Anorexia (1/151) 
Headache (12/151) 
Nausea (13/151) 
Vomiting (18/151) 
Weight gain (4/151) 
Taste disorder 
(2/151) 
Unspecified 
(28/151) 
151 172/1718 21/1718 
Drug Reported 
circulatory 
events 
Reported 
dermatological 
events 
Reported 
gastrointestinal 
events 
Reported 
respiratory 
events 
Reported 
miscellaneous 
events 
Total reported 
drug related 
events 
Number of 
children 
experiencing 
AEs 
Number of 
children disc. 
drug due to 
AE (n=) 
Topicals (n = 25) – – – – – 0 0/25 0/25 
Total 
     
295 
individual 
events 
318/4856 
(6.5%) 
children 
50/4856 
(1.0%) 
children 
disc. 
 
a Recommened laboratory tests 
b Laboratory events recorded 
LFT, Liver function test; URTI, Upper respiratory tract infection; PVE, Pruritic vesiculopustular eruption; AP, Abdominal pain; Disc., discontinued; 
wks, weeks. 
 
Table 5 
Drug Dosage Duration 
Tablets 
 Fluconazole 6 mg/kg/day 3 and 6 weeks 
 Griseofulvin  
– microsized 
20–25 mg/kg/day ≥6 weeks; continue until clinically 
clear 
 Griseofulvin 
– ultramicrosized 
10–15 mg/kg/day ≥6 weeks; continue until clinically 
clear 
 Itraconazole 5 mg/kg/day Trichophyton spp.: 2–4 weeks 
Microsporum spp.: 4–6 weeks 
 Ketoconazole 4 mg/kg/day 12 weeks 
 Terbinafine tablets 
–250 mg 
4–6 mg/kg/day 
10–20 kg: 62.5 mg 
20–40 mg: 125 mg 
>40 kg: 250 mg 
T. tonsurans: 2–6 weeks 
M. canis: 8–12 weeks 
 Terbinafine granules  
– 125 mg and 187.5 mg 
<25 kg: 125 mg 
25–35 kg: 187.5 mg 
>35 kg: 250 mg 
FDA‐approved for children ≥4 years 
6‐week duration for all species 
Oral solution 
 Griseofulvin  
microsized ‐ (125 mg/5 mL) 
20–25 mg/kg/day ≥6 weeks; continue until clinically 
clear 
 Itraconazole 3 mg/kg/day 6 weeks 
 Fluconazole 3 to 6 mg/kg/day 3 weeks 
 
 
 
 
  
Table 6 
 
Drug Available as branded drug Available as generic drug Approved for tinea capitis in 
children (<18 years old) 
Griseofulvin Brazil, Italy, India, USA Italy, India, UK, USA South Africa, Brazil, Italy, USA 
Terbinafine South Africa, Brazil, 
Canada, Italy, India, USA 
Brazil, Canada, Italy, India, 
UK, USA 
South Africa, Brazil, Canada, 
USA 
Itraconazole South Africa, Brazil, 
Canada, Italy, India, USA 
South Africa, Brazil, Canada, 
Italy, India, UK, USA 
South Africa, Brazil 
Fluconazole South Africa, Brazil, 
Canada, Italy, India, USA 
South Africa, Brazil, Canada, 
Italy, India, UK, USA 
South Africa 
 
Global paediatric drug availability55-59 
 
